The abstract is read at the publisher; the summary is JClub's.
Far1 residues 310–319 (QLIRTADISC) immediately after Cks1-binding phospho-threonine T306 strengthen inhibition of Clb5-Cdk1, with I312 and I317 key for potency.
- Why it matters: Docking motifs explain much of CDK recognition, but how intervening sequences modulate inhibitor binding and multisite phosphorylation remains unclear.
- What they did: Using AlphaFold3 modeling plus biochemical assays and targeted mutations, the study tested Far1 310–319’s role in Clb5-Cdk1 inhibition and inserted this region into a Sic1-derived substrate between two phosphorylation sites.
- The result: The Far1 insertion increased doubly phosphorylated product accumulation by more than twofold while lowering overall phosphorylation rate, linking auxiliary interactions to altered phosphorylation dynamics.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.